- #ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupCHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Ind…Endpoints · 1mo ago↗ source
- Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontEli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront…Endpoints · 1mo ago↗ source
- #ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remainCHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment…